Navigation Links
Midwest Healthcare Startups Raise $996 Million in 2012
Date:1/7/2013

CLEVELAND, Jan. 7, 2013 /PRNewswire/ -- Midwest healthcare companies attracted $996 million in new investments across 182 companies in 2012 according to the BioEnterprise Midwest Healthcare Venture Investment Report.  The total dollars attracted is up by twenty-three percent from 2011. Ohio ($292 million), Minnesota ($165 million), and Illinois ($146 million) led Midwestern states in attracting investment dollars; Cleveland, Minneapolis, and Chicago were the leaders among Midwest regions.

(Logo:  http://photos.prnewswire.com/prnh/20101028/DC90488LOGO )

"Investment activity in Midwest healthcare deals continues its upward trend, outperforming previous years' activity for 3 years in a row.
As with the rest of the country, Midwest healthcare investing fell dramatically in 2009 after strong years in 2007 and 2008, but it appears investors are again optimistic about Midwest deals. 2013 should be an interesting year to watch," said Aram Nerpouni, Interim President of BioEnterprise, the Cleveland biomedical accelerator.

By sector, the 2012 equity funding was allocated as follows:

  • Medical device companies:  $309 million (32%)
  • Healthcare IT and service companies: $177 million (18%)
  • Biopharmaceutical companies: $487 million (50%)
  • "The Midwest typically sees more medical device companies than either healthcare IT or biopharmaceutical; however, biotech saw the largest influx of dollars in 2012 as investors continue to focus on  later stage biotech opportunities," said Nerpouni.  "Investment activity in Midwest healthcare IT remains robust as investors are drawn by payers and providers searching for applications to improve patient outcomes and efficiencies."

    The Midwest Healthcare Venture Investment Report includes all reported numbers and regionally collected data. For co
    '/>"/>

    SOURCE BioEnterprise Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
    2. BioSpace Spotlights the growing Midwest Life Science Community
    3. Karmanos Cancer Center first in Midwest to offer latest Molecular Breast Imaging
    4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    5. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
    6. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
    7. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
    8. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
    9. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
    10. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
    11. ViroPharma to Participate in Two December Healthcare Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
    (Date:6/18/2013)... , June 18, 2013 ... investment research firm, announces the initiation of ... French biopharmaceutical company developing and marketing products ... indications.      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... report examining the investment merits of BioAlliance ...
    (Date:6/18/2013)... June 18, 2013 Mapi Pharma Ltd. ... and innovative intermediates, and finished dosage forms based on selected ... granted a United States patent for ... Europe for the oral treatment of moderate-to-severe acute ... Intermediate Compounds and Processes for the Preparation of Tapentadol ...
    (Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
    Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
    ... Conference Call at 12:30 p.m. Eastern Time, September 19, ... ... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that Allergan, Inc.,(NYSE: ... States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with,Allergan,s acquisition of ...
    ... announced that it has filed a registration statement on Form,S-1 ... proposed,initial public offering of its common stock. All of ... The,number of shares to be offered and the price range ... to apply to have its common stock,approved for quotation on ...
    ... 19 ,Arpida Ltd (SWX: ARPN) was invited to ... new antimicrobial agents at the 47th annual,Interscience Conference ... is a major scientific conference where thousands of,scientists ... to discuss the,latest developments in the field of ...
    Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
    (Date:6/18/2013)... has awarded $12.7 million to match nine academic ... compounds to explore new treatments for patients in ... dystrophy and schizophrenia. The collaborative pilot initiative, called ... led by the National Center for Advancing Translational ... Fund. , The process of developing a new ...
    (Date:6/18/2013)... of breast and ovarian cancers are familial in origin, ... to inherited mutations from the parents in genes such ... PARP inhibitors, which are currently in clinical trials, have ... for personalised cancer treatment, an alternative to standard chemotherapy. ... these patients generate resistance to the drug and, therefore, ...
    (Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
    Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
    ... 15, 2011 BGI, the world,s largest genomics organization, ... Oregon State University to conduct collaborative de novo genome ... plant pathogens. This agreement kicks off a larger ... Genus Sequencing Consortium, to conduct collaborative de novo genome ...
    ... even in the cloudiest conditions, while the lush interiors ... canopy. The ability of trees to adapt to light ... photosynthesis in poor light, has been explored by Czech ... Functional Ecology . The research centers around the ...
    ... In a review study, researchers from Tufts University ... use of antibiotics in food animals and fish farming ... the preponderance of evidence argues for stricter regulation of ... resistance, notes that a guiding tenet of public health, ...
    Cached Biology News:BGI announces collaborative research agreements with Oregon State University 2Trees adapt to poor levels of sunlight to effectively process carbon, study shows 2Evidence supports ban on growth promotion use of antibiotics in farming 2Evidence supports ban on growth promotion use of antibiotics in farming 3Evidence supports ban on growth promotion use of antibiotics in farming 4
    ...
    Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    IHC detection kit for BrdU in cells and tissues...
    The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
    Biology Products: